Coexistence of factor V Leiden and primary antiphospholipid syndrome: A patient with recurrent myocardial infarctions and thrombocytopenia

Zeitschrift fur Kardiologie

Volumn 89, Issue 12, 2000, Pages 1067-1071

  Schutt M ^a   Kluter H ^a   Wiedemann, G J ^a   Richardt, G ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Activated protein C resistance; Antiphospholipid syndrome; Coronary artery disease; Factor V Leiden

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; COUMARIN;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; GENETIC ANALYSIS; HEART INFARCTION; HUMAN; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; THROMBOCYTOPENIA;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; BLOOD COAGULATION TESTS; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; FACTOR V; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; RISK FACTORS; THROMBOCYTOPENIA;

EID: 0034515453     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920070133     Document Type: Article

References (21)

1. The presence of antiphospholipid antibodies in acute myocardial infarction
2. Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome
3. Factor V (Arg 506→G1n) mutation in young survivors of myocardial infarction
4. The "primary" antiphospholipid syndrome: Major clinical and serological features
5. DNA typing of human platelet antigen systems 1, 2, 3 and 5 in B-lymphoblastold cell lines of the international histocompatibility workshop
6. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells
7. Coexistence of familial antiphospholipid syndrome and factor V Leiden: Impact on thrombotic diathesis
8. New molecular insights into the genetics of thrombophilia
9. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A
10. Use of a simplified dilute Russell viper venom time (dRVVT) confirms heterogeneity among "Lupus Anticoagulants"
11. Thrombocytopenia in the antiphospholipid syndrome: Pathophysiology, clinical relevance and treatment
12. Activated protein C resistance: Molecular mechanisms
13. Spontaneous venous thrombosis in a young patient with combined factor V Leiden and lupus anticoagulant
14. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation
15. Antiphospholipid antibodies and thrombosis: Assessment of the potential risk for thrombosis
16. Resistance to activated protein C and risk of premature myocardial infarction
17. Familial coexistence of primary antiphospholipid syndrome and factor V Leiden
18. Ischemic stroke due to transient thrombosis of the internal carotid artery in a patient with combined antiphospholipid syndrome and factor V Leiden
19. The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant
20. Antiphospholipid antibodies and myocardial infarction